Literature DB >> 11788244

Concomitant clozapine reduces smoking in patients treated with risperidone.

Ric M Procyshyn1, Gordon Tse, Osric Sin, Sean Flynn.   

Abstract

This pilot study examines the smoking behaviors of patients treated with either risperidone alone or in combination with clozapine. Smoking behavior was evaluated using expired carbon monoxide (CO) measurements, the Fagerstrom Test for Nicotine Dependence (FTND), and a semi-structured interview. Our results indicate that patients co-prescribed clozapine with risperidone smoke significantly less than patients treated with risperidone alone (19.1+/-9.3 vs. 37.8+/-19.1 ppm CO, respectively, P=0.03). These data are consistent with previous studies showing that clozapine treatment is associated with significantly reduced smoking behavior relative to other antipsychotic agents.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11788244     DOI: 10.1016/s0924-977x(01)00130-4

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  13 in total

1.  Predictors of smoking reduction outcomes in a sample of 287 patients with schizophrenia spectrum disorders.

Authors:  Bo-Jian Wu; Tsuo-Hung Lan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-08-27       Impact factor: 5.270

Review 2.  Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism?

Authors:  Robert M Roth; Mary F Brunette; Alan I Green
Journal:  Curr Psychiatry Rep       Date:  2005-08       Impact factor: 5.285

Review 3.  Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms.

Authors:  Joseph T Coyle
Journal:  Neurotox Res       Date:  2006-12       Impact factor: 3.911

4.  Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders.

Authors:  Mary F Brunette; Robert E Drake; Haiyi Xie; Gregory J McHugo; Alan I Green
Journal:  Schizophr Bull       Date:  2006-06-16       Impact factor: 9.306

Review 5.  The role of antipsychotics in smoking and smoking cessation.

Authors:  Annette M Matthews; Vanessa B Wilson; Suzanne H Mitchell
Journal:  CNS Drugs       Date:  2011-04       Impact factor: 5.749

6.  Antipsychotic Treatment and Tobacco Craving in People With Schizophrenia.

Authors:  Heidi J Wehring; Stephen J Heishman; Robert P McMahon; Fang Liu; Stephanie Feldman; Heather Raley; Elaine Weiner; Deanna L Kelly
Journal:  J Dual Diagn       Date:  2017 Jan-Mar

Review 7.  Risperidone augmentation of clozapine: a critical review.

Authors:  Vassilis P Kontaxakis; Panayotis P Ferentinos; Beata J Havaki-Kontaxaki; Konstantinos G Paplos; Dimitra A Pappa; George N Christodoulou
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-08-08       Impact factor: 5.270

8.  Olanzapine improves deficient sensory inhibition in DBA/2 mice.

Authors:  Johanna K Simosky; Robert Freedman; Karen E Stevens
Journal:  Brain Res       Date:  2008-07-25       Impact factor: 3.252

9.  The Wisconsin Predicting Patients' Relapse questionnaire.

Authors:  Daniel M Bolt; Megan E Piper; Danielle E McCarthy; Sandra J Japuntich; Michael C Fiore; Stevens S Smith; Timothy B Baker
Journal:  Nicotine Tob Res       Date:  2009-04-16       Impact factor: 4.244

Review 10.  Comorbidity of substance abuse with other psychiatric disorders.

Authors:  Tomas Palomo; Trevor Archer; Richard M Kostrzewa; Richard J Beninger
Journal:  Neurotox Res       Date:  2007-07       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.